CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Exclusion Criteria

• •Severe active central nervous system lupus
• •Malignancy within past 5 years
• •Known to be positive for HIV and/or positive at the screening visit for hepatitis B, or hepatitis C
• •Comorbidities that would interfere with evaluations of study drug effect
• •Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections
• •History of active tuberculosis or a history of tuberculosis infection
• •Pregnant or nursing